CoChat

A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia

Open access
Papanicolaou, Dimitris A., Ather, S.N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B.B., Chandler, J. · 2013 · The Journal of nutrition, health and aging

The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Sarcopenia, the age-related loss of muscle mass [defined as appendicular LBM/Height2 (aLBM/ht2) below peak value by>1SD], strength and function, is a major contributing factor to frailty in the elderly. MK-0773 is a selective androgen receptor modulator designed to improve muscle function while minimizing effects on other tissues. OBJECTIVES: The primary objective of this study was to demonstrate an improvement in muscle strength and lean body mass (LBM) in sarcopenic frail elderly women treated with MK-0773 relative to placebo. DESIGN: This was a randomized, double-blind, parallel-arm, placebo-controlled, multicenter, 6-month study. Participants were randomized in a 1:1 ratio to receive either MK-0773 50mg b.i.d. or placebo; all participants received Vitamin D and protein supplementation. SETTING: General community. PARTICIPANTS: 170 Women aged ≥65 with sarcopenia and moderate physical dysfunction. MEASUREMENTS: Dual energy X-ray absorptiometry, muscle strength and power, physical performance measures. RESULTS: Participants receiving MK-0773 showed a statistically significant increase in LBM from baseline at Month 6 vs. placebo (p<0.001). Participants receiving both MK-0773 and placebo showed a statistically significant increase in strength from baseline to Month 6, but the mean difference between the two groups was not significant (p=0.269). Both groups showed significant improvement from baseline at Month 6 in physical performance measures, but there were no statistically significant differences between participants receiving MK-0773 and placebo. A greater number of participants experienced elevated transaminases in the MK-0773 group vs. placebo, which resolved after discontinuation of study therapy. MK-0773 was generally well-tolerated with no evidence of androgenization. CONCLUSIONS: The MK-0773-induced increase in LBM did not translate to improvement in strength or function vs. placebo. The improvement of strength and physical function in the placebo group could be at least partly attributed to protein and vitamin D supplementation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12603-013-0335-x

Cites

50 of 50 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Participant accounting
Figure 1 Participant accountingCC BY-NC-ND · PubMed Central
Figure 2 Change from baseline (+/-SE) in a) LBM (kg); b) appendicular LBM(Kg); c) leg press measurement (lb.); d) gait speed (cm/sec); e) stair climbing power (watt); f) AM-PAc physical movement score; g) AM-PAc personal care score; h) SPPB composite score; i)total fat (kg); j) total bone mineral content (kg), by visit during 6 months on treatment
Figure 2 Change from baseline (+/-SE) in a) LBM (kg); b) appendicular LBM(Kg); c) leg press measurement (lb.); d) gait speed (cm/sec); e) stair climbing power (watt); f) AM-PAc physical movement score; g) AM-PAc personal care score; h) SPPB composite score; i)total fat (kg); j) total bone mineral content (kg), by visit during 6 months on treatmentCC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 50 references

Cited by

See all 212

Metadata

Authors
Papanicolaou, D. A., Ather, S. N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B. B., & Chandler, J.
Affiliations
  • Novartis (United States) (US)
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Corresponding author
Papanicolaou, Dimitris A.
Venue
The Journal of nutrition, health and aging
Publisher
Elsevier BV
Published
2013-06
Volume
17
Issue
6
Pages
533-543
ISSN
1279-7707 (ISSN-L)
OpenAlex
W2064936259
Cited by
196
References
49
Citations by year
2026: 18 · 2025: 19 · 2024: 18 · 2023: 24 · 2022: 11 · 2021: 13 · 2020: 23 · 2019: 15 · 2018: 15 · 2017: 14 · 2016: 9 · 2015: 7 · 2014: 7 · 2013: 2
FWCI
6.03
Type
journal article
Language
en
Open access
Licence
Locations
  • The journal of nutrition health & aging (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Nutrition and Health in Aging
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Muscle Physiology and Disorders
Keywords
sarcopenia, selective androgen receptor modulators, lean body mass, muscle strength, physical performance, frail elderly women, protein supplementation, vitamin D supplementation, transaminase elevation, androgenization, muscle mass
MeSH terms
Aged, Aged, 80 and over, Azasteroids, Body Composition, Dietary Proteins, Dose-Response Relationship, Drug, Double-Blind Method, Female, Humans, Musculoskeletal Physiological Phenomena, Receptors, Androgen, Vitamin D, Absorptiometry, Photon, Frail Elderly, Muscle, Skeletal, Dietary Supplements, Muscle Strength, Sarcopenia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. https://app.cochat.ai/papers/10.1007/s12603-013-0335-x
The paper
Papanicolaou, D. A., Ather, S. N., Zhu, H., Zhou, Y., Lutkiewicz, J., Scott, B. B., & Chandler, J. (2013). A phase IIA randomized, placebo-controlled clinical trial to study the efficacy and safety of the selective androgen receptor modulator (SARM), MK-0773 in female participants with sarcopenia. The Journal of nutrition, health and aging. https://doi.org/10.1007/s12603-013-0335-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.